Omeprazole

Generic Name
Omeprazole
Brand Names
Konvomep, Losec, Omeclamox, Omesec, Previdolrx Analgesic Pak, Prilosec, Talicia, Yosprala, Zegerid, Zegerid Reformulated Aug 2006, Zegerid With Magnesium Hydroxide
Drug Type
Small Molecule
Chemical Formula
C17H19N3O3S
CAS Number
73590-58-6
Unique Ingredient Identifier
KG60484QX9
Background

Originally approved by the FDA in 1989, omeprazole is a proton-pump inhibitor, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class, and its approva...

Indication

Omeprazole, according to the FDA label is a proton pump inhibitor (PPI) used for the following purposes:

• Treatment of active duodenal ulcer in adults

• Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer

recurrence in adults

• Treatment of active benign gastric ulcer in adults
...

Associated Conditions
Ankylosing Spondylitis (AS), Duodenal Ulcer, Erosive Esophagitis, Gastric Ulcer, Gastro-esophageal Reflux Disease (GERD), Healing, Heartburn, Helicobacter Pylori Infection, Osteoarthritis (OA), Rheumatoid Arthritis, Upper GI Bleeding, Zollinger-Ellison Syndrome, Benign, active Gastric Ulcer, Develop NSAID-induced gastric ulcers, Hypersecretory conditions, Multiple endocrine adenomas
Associated Therapies
-

Biomarkers for Prediction of Analgesic Efficacy in Knee OA.

First Posted Date
2022-02-25
Last Posted Date
2024-04-12
Lead Sponsor
Rambam Health Care Campus
Target Recruit Count
17
Registration Number
NCT05256342
Locations
🇮🇱

Rambam Health Care Campus, Haifa, Israel

A Study to Investigate the Effect of Single and Repeated Oral Doses of ACT-539313 on What the Body Does to Flurbiprofen, Omeprazole, Midazolam in Healthy Subjects

First Posted Date
2022-02-24
Last Posted Date
2022-05-04
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
Target Recruit Count
22
Registration Number
NCT05254548
Locations
🇩🇪

CRS Clinical Research Services Berlin GmbH, Berlin, Germany

Efficacy of Linaclotide in Patients With Overlapping Functional Gastrointestinal Disorders

First Posted Date
2021-11-26
Last Posted Date
2021-12-13
Lead Sponsor
RenJi Hospital
Target Recruit Count
78
Registration Number
NCT05134584
Locations
🇨🇳

RenJiH, Shanghai, Shanghai, China

Study of the Effect of Food and a Proton Pump Inhibitor (PPI; Omeprazole) on LOXO-305 in Healthy Participants

Phase 1
Completed
Conditions
Interventions
First Posted Date
2021-11-24
Last Posted Date
2021-11-24
Lead Sponsor
Loxo Oncology, Inc.
Target Recruit Count
10
Registration Number
NCT05134350
Locations
🇺🇸

Covance Clinical Research Unit, Daytona Beach, Florida, United States

A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults

First Posted Date
2021-11-05
Last Posted Date
2021-11-05
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
72
Registration Number
NCT05109390
Locations
🇺🇸

Clinical Trial Site, Tempe, Arizona, United States

A Study to Estimate the Effect of Multiple Dose Abrocitinib on Caffeine, Efavirenz, and Omeprazole in Healthy Participants

First Posted Date
2021-10-05
Last Posted Date
2024-05-31
Lead Sponsor
Pfizer
Target Recruit Count
26
Registration Number
NCT05067439
Locations
🇺🇸

Research Centers of America ( Hollywood ), Hollywood, Florida, United States

A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib

First Posted Date
2021-07-13
Last Posted Date
2022-09-16
Lead Sponsor
AstraZeneca
Target Recruit Count
5
Registration Number
NCT04959266
Locations
🇪🇸

Research Site, Malaga, Spain

High Dose Omeprazole in Patients With Pancreatic Cancer

Early Phase 1
Recruiting
Conditions
Interventions
First Posted Date
2021-06-18
Last Posted Date
2024-08-16
Lead Sponsor
University of Oklahoma
Target Recruit Count
60
Registration Number
NCT04930991
Locations
🇺🇸

Stephenson Cancer Center, Oklahoma City, Oklahoma, United States

A Study to Evaluate the One-way Interaction of Calcium Carbonate, Omeprazole, or Rifampin on ACP-196

First Posted Date
2021-06-07
Last Posted Date
2021-06-07
Lead Sponsor
Acerta Pharma BV
Target Recruit Count
72
Registration Number
NCT04914936

A Study to Evaluate the Effect of an Acidic Formulation of Acalabrutinib (ACP-196), Acidic Beverage, or Grapefruit Juice on the Pharmacokinetics (PK) of ACP-196 Alone and Coadministered With Omeprazole

Phase 1
Completed
Conditions
Interventions
First Posted Date
2021-05-07
Last Posted Date
2021-05-07
Lead Sponsor
Acerta Pharma BV
Target Recruit Count
36
Registration Number
NCT04876807
Locations
🇺🇸

Laura Sterling, MD, MPH, Lincoln, Nebraska, United States

© Copyright 2024. All Rights Reserved by MedPath